Price movement over the last 24 hours
Abeona Therapeutics Inc vs PayPal Holdings, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while PayPal Holdings, Inc. trades at $44.49 (market cap $40.27B). The key difference: PayPal Holdings, Inc. is far larger — about 107.9× Abeona Therapeutics Inc's market cap, and PayPal Holdings, Inc. pays a 1.23% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | PYPL | |
|---|---|---|
Market Cap | $373.32M | $40.27B |
Sector | Health | Financials |
52-Week High | $7.23 | $78.22 |
52-Week Low | $4.17 | $39.08 |
Enterprise Value | $228.22M | $40.34B |
Dividend Yield | — | 1.23% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
PayPal trades at $45.65, up 0.4% with a bullish technical outlook. The stock appears undervalued with a P/E of 8.46 and strong profitability metrics including 15% net income margin and 25.12% ROE. Recent earnings beat expectations in Q1 2026, and the company maintains robust cash flow generation of $6.4B from operations. Analyst consensus is mixed with 37% buy ratings but a $49 price target suggesting 7% upside potential.
PayPal presents a value opportunity with attractive valuation multiples and solid fundamentals, though growth moderation and competitive pressures remain concerns. The stock's technical strength and dividend initiation provide support, while legal scrutiny and execution risks warrant monitoring. Upside appears limited near-term but long-term prospects remain favorable if management delivers on growth initiatives.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →